Pd49-11 Combining Neddylation Inhibition With Chemotherapy to Treat Renal Medullary Carcinoma
Year: 2021
Type: article
Abstract: INTRODUCTION AND OBJECTIVE:The survival of patients with metastatic renal cell carcinoma (mRCC) is < 10% at 5-years, despite treatment.Hyaluronic acid (HA) promotes tumor growth and metastasis through its receptors CD44 and RHAMM.4methylumbelliferone (MU) is a nonÀtoxic small molecule HA
Source: The Journal of Urology
Authors: Daniel Shapiro, Niki Millward Zacharias, Durga Tripathi, Jean-Philippe Bertocchio, Melinda Soeung, Priya Rao, Cheryl Walker, Giannicola Genovese, Nizar Tannir, Christopher Wood, Jose Karam, Pavlos Msaouel
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W3190056898